{
  "id": 9543880,
  "title": "Rodman & Renshaw initiates Quince Therapeutics stock with buy rating",
  "url": "https://urgent.news/2026/09/24/rodman-renshaw-initiates-quince-therapeutics-stock-with-buy-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-24T11:20:44.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/rodman--renshaw-initiates-quince-therapeutics-stock-with-buy-rating-93CH-4915126"
  },
  "original_language": "en",
  "account": "Investing.com reports that Rodman & Renshaw has initiated coverage on Quince Therapeutics Inc. (NASDAQ: QNCX) with a Buy rating, setting an ambitious target price of $70.00 per share. This implies a potential 130% upside from the current trading price of $30.15, which values the company at a mere $30.7 million market cap.\n\nRodman & Renshaw believes Quince's LAM-001 therapy, a novel once-daily dry-powder inhaler for mTOR inhibition, holds significant promise for pulmonary diseases such as PH-ILD, BOS, and SAPH. The firm notes that Phase 2 data for the BOS indication is anticipated in Q1 2027, while Phase 2b data for PH-ILD is expected in Q1 2028.\n\nThe company is currently holding a robust $116 million in cash, comfortably surpassing its debt and boasting an impressive current ratio of 14.52. However, the cash is being rapidly depleted, with levered free cash flow at -$47 million. Despite this, Rodman & Renshaw remains confident that positive Phase 2 trial results could propel the stock to new heights.\n\nRecent developments include a special shareholders meeting to vote on raising more shares and converting preferred stock, potentially reshaping the company's control structure. Additionally, Quince's stock has received a Market Outperform rating from Citizens, following its merger with Orphai Therapeutics, and an Overweight rating from Cantor Fitzgerald, both citing the company's promising pipeline. Moreover, Quince has established a Scientific Advisory Board, bolstering its development efforts for LAM-001.",
  "summary": null,
  "key_points": [
    "Rodman & Renshaw initiates Quince Therapeutics with Buy rating",
    "Targets $70.00 per share, 130% upside from $30.15 price",
    "LAM-001 therapy for pulmonary diseases shows Phase 2 data in 2027"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}